403 related articles for article (PubMed ID: 18436144)
1. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.
Paumelle R; Staels B
Trends Cardiovasc Med; 2008 Apr; 18(3):73-8. PubMed ID: 18436144
[TBL] [Abstract][Full Text] [Related]
2. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
3. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
4. The treatment of dyslipidemia--what's left in the pipeline?
Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet actions of statins and fibrates are mediated by PPARs.
Ali FY; Armstrong PC; Dhanji AR; Tucker AT; Paul-Clark MJ; Mitchell JA; Warner TD
Arterioscler Thromb Vasc Biol; 2009 May; 29(5):706-11. PubMed ID: 19150877
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
7. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway.
Paumelle R; Blanquart C; Briand O; Barbier O; Duhem C; Woerly G; Percevault F; Fruchart JC; Dombrowicz D; Glineur C; Staels B
Circ Res; 2006 Feb; 98(3):361-9. PubMed ID: 16397146
[TBL] [Abstract][Full Text] [Related]
8. Fibrate therapy: an update.
Remick J; Weintraub H; Setton R; Offenbacher J; Fisher E; Schwartzbard A
Cardiol Rev; 2008; 16(3):129-41. PubMed ID: 18414184
[TBL] [Abstract][Full Text] [Related]
9. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
10. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.
Carmena R
Am Heart J; 2005 Nov; 150(5):859-70. PubMed ID: 16290951
[TBL] [Abstract][Full Text] [Related]
11. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
12. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.
Okopień B; Krysiak R; Kowalski J; Madej A; Belowski D; Zieliński M; Herman ZS
J Cardiovasc Pharmacol; 2005 Sep; 46(3):377-86. PubMed ID: 16116345
[TBL] [Abstract][Full Text] [Related]
13. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
[TBL] [Abstract][Full Text] [Related]
14. Managing dyslipidemia in chronic kidney disease.
Harper CR; Jacobson TA
J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
[TBL] [Abstract][Full Text] [Related]
15. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
16. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
17. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
[TBL] [Abstract][Full Text] [Related]
18. The effects of statins on endothelium, inflammation and cardioprotection.
Elrod JW; Lefer DJ
Drug News Perspect; 2005 May; 18(4):229-36. PubMed ID: 16034478
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of statins and related pharmacological experimental approaches.
Alegret M; Silvestre JS
Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
[TBL] [Abstract][Full Text] [Related]
20. Lipid abnormalities and cardiovascular risk in the elderly.
Milionis HJ; Elisaf MS; Mikhailidis DP
Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
